Cadrenal Therapeutics will be engaging with the FDA in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients. Left Ventricular Assist Devices – LVADs – are mechanical pumps to support heart function in patients with advanced heart failure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVKD:
- Cadrenal Therapeutics Inc trading resumes
- Cadrenal Therapeutics Inc trading halted, volatility trading pause
- Cadrenal Therapeutics Inc trading halted, news pending
- Cadrenal Therapeutics Partners with Abbott on Cardiac Trial
- Cadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin